MGX
Metagenomi Therapeutics, Inc.
CIK 0001785279 · Biological Products, (No Diagnostic Substances)
Z″ LOWER ZONE
Z′ -0.90
Net margin
-348.5%
as of 2025-12-31
Operating margin
-380.9%
as of 2025-12-31
Revenue YoY growth
-51.8%
as of 2025-12-31
Provenance: MGX’s most recent Revenue
$25,210,000
- Filing
- 0001193125-26-093976 (10-K)
- Period
- 2025-01-01 to 2025-12-31
- XBRL tag
- us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Context
- C_2bd5f353-3ab9-4e02-a9e4-39d989f093ed
- Mapping
- seed · confidence 1.00